Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective

Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective

Aim: The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared...

Full description

Bibliographic Details
Main Authors:	Brian Murray, Jennifer Miles-Thomas, Amy J Park, Victor B Nguyen, Amy Tung, Patrick Gillard, Anjana Lalla, Victor W Nitti, Christopher J Chermansky
Format:	Article
Language:	English
Published:	Becaris Publishing Limited 2023-01-01
Series:	Journal of Comparative Effectiveness Research
Subjects:	anticholinergic β3-adrenoceptor agonist cost–effectiveness markov model onabotulinumtoxina overactive bladder quality-adjusted life-year rechargeable sacral nerve stimulation

Similar Items

Mirabegron in the Management of Overactive Bladder Syndrome
by: O'Kane M, et al.
Published: (2022-09-01)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
by: Yuh-Chen Kuo, et al.
Published: (2023-01-01)

Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis
by: Chi-Wen Lo, et al.
Published: (2020-02-01)

Time Course of Treatment for Primary Enuresis With Overactive Bladder
by: Young Jae Im, et al.
Published: (2018-06-01)

Retrospective Observational Study of Treatment Patterns and Efficacy of onabotulinumtoxinA Therapy in Patients with Refractory Overactive Bladder in Clinical Practice
by: Kwang Jin Ko, et al.
Published: (2023-05-01)

Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience
by: N K Mohanty, et al.
Published: (2008-01-01)

Overactive bladder – 18 years – Part II
by: Jose Carlos Truzzi, et al.
Published: (2016-04-01)

A Feasibility Study to Evaluate Changes in Urinary Metabolites after OnabotulinumtoxinA Injection for Refractory Overactive Bladder
by: Laura M. Tellechea, et al.
Published: (2022-09-01)

Sacral Neuromodulation in Treating Overactive Bladder Patients – First-Time Application in Croatia
by: Mirko Bakula, et al.
Published: (2023-01-01)

The Impact of Anticholinergic Use for Overactive Bladder on Cognitive Changes in Adults with Normal Cognition, Mild Cognitive Impairment, or Dementia
by: Blayne Welk, et al.
Published: (2022-12-01)

Adverse Events of Intravesical Onabotulinum Toxin A Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
by: Yuh-Chen Kuo, et al.
Published: (2016-03-01)

Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study
by: Hoon Choi, et al.
Published: (2018-03-01)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
by: Makhani A, et al.
Published: (2020-04-01)

An examination of Overactive Bladder Syndrome: present comprehension, methods of treatment, and innovative approaches
by: Zuzanna Kotowicz, et al.
Published: (2024-03-01)

A Korean Postmarketing Study Assessing the Effectiveness of OnabotulinumtoxinA for the Treatment of Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder Using a Validated Patient-Reported Outcome Measure
by: Kwang Jin Ko, et al.
Published: (2019-03-01)

Low dose intradetrusor injections of onabotulinumtoxinA in women with overactive bladder symptoms or the painful bladder syndrome: unfavorable balance between clinical efficacy and the need for catheterization
by: Jan Groen, et al.
Published: (2012-10-01)

Hyperactive bladder: concept of disease and paradigms in the treatment
by: G. G. Krivoborodov, et al.
Published: (2021-04-01)

Effects of Acute Sacral Neuromodulation at Different Frequencies on Bladder Overactivity in Pigs
by: Xing Li, et al.
Published: (2017-06-01)

Low dose intradetrusor injections of onabotulinumtoxina in women with overactive bladder symptoms or the painful bladder syndrome: unfavourable balance between clinical efficacy and the need for catheterisation
by: Jan Groen, et al.
Published: (2012-01-01)

Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation
by: Hamilton Trinh, et al.
Published: (2019-09-01)

Effects of Acute Sacral Neuromodulation at Different Pulse Widths on Bladder Overactivity in Pigs
by: Huiling Cong, et al.
Published: (2019-06-01)

Sacral neuromodulation in overactive bladder: a review and current perspectives
by: Sukhu T, et al.
Published: (2016-10-01)

Trigonal-Sparing vs. Trigonal-Involved OnabotulinumtoxinA Injection for the Treatment of Overactive Bladder: A Systematic Review and Meta-Analysis
by: Yuanshan Cui, et al.
Published: (2021-10-01)

Exploring Concomitant Acetylcholinesterase Inhibitor and Overactive Bladder Anticholinergic Use and Risk of Hospitalization in Medicare and Dual-Eligible Medicare–Medicaid Populations in a Historic Database
by: Jonathan H. Watanabe, et al.
Published: (2023-09-01)

Solifenacin in overactive bladder syndrome: pharmacoeconomic analysis
by: Sergio Iannazzo, et al.
Published: (2008-03-01)

Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
by: Hiroshi Nakagomi, et al.
Published: (2022-03-01)

An overlooked effect of systemic anticholinergics: alteration on accommodation amplitude
by: Mehmet Ali Sekeroglu, et al.
Published: (2016-05-01)

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
by: Xin Zhou, et al.
Published: (2015-01-01)

The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA
by: Waleed Al Taweel, et al.
Published: (2015-01-01)

Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis
by: Hejia Yuan, et al.
Published: (2017-03-01)

Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis
by: Guang-Ping Li, et al.
Published: (2018-12-01)

Overactive bladder in an integrated delivery system: a longitudinal cohort study
by: Jeffrey A. Linder, et al.
Published: (2020-05-01)

Do Failure of Posterior Tibial Nerve Stimulation Precludes to Use Sacral Neuromodulation in Patient With Overactive Bladder?
by: Louis-Paul Berthelot, et al.
Published: (2019-12-01)

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility
by: Chung-Cheng Wang, et al.
Published: (2016-03-01)

Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy
by: Nathan Hoag, et al.
Published: (2016-03-01)

Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?
by: Ömer Acar, et al.
Published: (2019-06-01)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01)

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
by: Frankel J, et al.
Published: (2022-03-01)

Therapeutic Efficacy of onabotulinumtoxinA Delivered Using Various Approaches in Sensory Bladder Disorder
by: Po-Yen Chen, et al.
Published: (2020-01-01)

Neuromodulation – a therapeutic option for refractory overactive bladder. A recent literature review
by: Jacek K. Szymański, et al.
Published: (2019-05-01)